Rimegepant: Oral CGRP Antagonist for Migraine Treatment and Prevention
Rimegepant is an orally administered small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, belonging to the gepant drug class. It holds a unique dual approval for both the acute treatment of migraine attacks and their prevention with every-other-day dosing, making it the first oral drug approved for both indications in the same patient.
Unlike triptans, rimegepant does not cause vasoconstriction, which makes it suitable for migraine patients with cardiovascular disease or contraindications to serotonin agonists. Additionally, gepants including rimegepant do not appear to cause medication overuse headache (MOH), a significant limitation of triptans and non-steroidal anti-inflammatory drugs used for acute migraine.
Mechanism of Action
CGRP is a neuropeptide released from trigeminal nerve endings during migraine attacks. It is a potent vasodilator and pain sensitizer that plays a central role in migraine pathophysiology. Rimegepant competitively and selectively blocks the CGRP receptor (specifically the CGRP receptor composed of calcitonin receptor-like receptor and receptor activity-modifying protein 1), preventing CGRP from inducing vasodilation and neurogenic inflammation in intracranial vessels and the trigeminal system. This mechanism is distinct from triptans, which act as serotonin 5-HT1B/1D agonists causing vasoconstriction. Rimegepant does not constrict blood vessels, which is central to its cardiovascular safety advantage.
Indications
Rimegepant is approved for acute treatment of migraine with or without aura in adults. It is additionally approved for preventive treatment of episodic migraine in adults, taken every other day on migraine-free days. This dual indication allows patients to use the same drug both to treat breakthrough attacks and to reduce overall attack frequency. It represents a particularly valuable option for patients with cardiovascular risk factors, those who have failed or are intolerant of triptans, and those concerned about medication overuse headache with frequent acute therapy.
Dosage and Administration
For acute treatment: 75 mg taken orally as a single dose at the onset of a migraine attack. A second dose may be taken if the headache returns, but the total daily dose should not exceed 75 mg on acute treatment days. For preventive therapy: 75 mg taken every other day on non-treatment days. The orally disintegrating tablet (ODT) formulation dissolves on the tongue without water, which is practical during nausea associated with migraine attacks. Rimegepant can be taken with or without food. No dose adjustment is required for mild to moderate renal or hepatic impairment.
Side Effects
Rimegepant is generally well tolerated. Nausea is the most frequently reported adverse effect, occurring in approximately two percent of patients in clinical trials. Urinary tract infection has been reported with slightly higher frequency in rimegepant-treated patients than in placebo groups. Allergic reactions including facial swelling and dyspnoea have been reported rarely and warrant immediate medical attention. No cardiovascular adverse events attributable to vasoconstriction have been identified in clinical trials, consistent with the non-vasoconstrictive mechanism. Long-term safety data are available from extension studies lasting up to one year.
Interactions
Rimegepant is metabolised primarily by CYP3A4 and is a substrate of P-glycoprotein and BCRP transporters. Strong CYP3A4 inhibitors such as itraconazole and clarithromycin can increase rimegepant exposure significantly; the combination should be avoided or the dose reduced. Strong CYP3A4 inducers such as rifampicin and carbamazepine reduce rimegepant levels and may reduce efficacy. Combined use with other CGRP pathway antagonists (other gepants or anti-CGRP monoclonal antibodies) is not recommended due to lack of safety data. Hormonal contraceptives can modestly increase rimegepant exposure.
Special Notes
Rimegepant is a prescription-only medicine. It should not be used in severe hepatic impairment. Use during pregnancy is not recommended due to lack of human data; animal studies showed adverse embryo-foetal effects. Breastfeeding should be avoided during treatment and for five days after the last dose. CGRP has physiological roles in various tissues, and the long-term effects of persistent CGRP blockade are still under investigation. Patients with a history of serious hypersensitivity reactions to any gepant should not use rimegepant. Unlike ergotamine derivatives and triptans, rimegepant can be used in patients with ischaemic heart disease under medical supervision.
Related Topics
Frequently Asked Questions
Why does rimegepant not cause medication overuse headache?
The exact mechanism is not fully understood, but gepants appear not to trigger the central sensitization processes that lead to MOH, unlike triptans and analgesics. This makes rimegepant particularly useful for patients who need frequent acute migraine treatment and are at risk of MOH with conventional drugs.
Can rimegepant be used by patients with heart disease?
Yes. Because rimegepant does not cause vasoconstriction, it is not contraindicated in patients with ischaemic heart disease, Raynaud's phenomenon, or uncontrolled hypertension, unlike triptans and ergotamines. It represents a major advance for migraine patients with cardiovascular conditions who previously had limited acute treatment options.
What is the difference between gepants and anti-CGRP monoclonal antibodies?
Both classes target the CGRP pathway, but anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab) are biologics given by injection monthly or quarterly for prevention only. Gepants are small oral molecules that work acutely and, in the case of rimegepant, also for prevention with every-other-day dosing.
Sources
- EMA: Rimegepant (Vydura) Summary of Product Characteristics 2022
- Lipton RB et al: Rimegepant prevention trial. N Engl J Med 2021
- EHF Migraine Guidelines 2022